Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Major change in NIH policy mandates inclusion of organoids, computational models, or other non-animal methods in proposals, likely …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
A phase 3 study reveals combining inavolisib with fulvestrant and palbociclib substantially delays progression and prolongs survival in …
Landmark ATOMIC trial shows combining immunotherapy and chemo improves outcomes for colon cancer patients with mismatch-repair deficiency
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
Already a subscriber? Log in